Patents Assigned to Celsense Inc.
  • Publication number: 20160296642
    Abstract: Compositions and methods for assessing inflammation in a subject. The present disclosure provides compositions for labeling leukocytes with a 19F-containing perfluoropolyether molecule ex vivo. In some examples, the leukocytes are obtained from the patient, enriched in a whole blood fraction, and then labeled. The labeled cells may be re-introduced into the patient. The leukocytes may accumulate at a site of inflammation, thus permitting non-invasive evaluation of inflammation in patients. The present methods provide a tool for assessing inflammation in a wide variety of autoimmune diseases and may have particular utility in intestinal diseases such as Crohn's disease, ulcerative colitis, inflammatory bowel disease, and cardio myositis.
    Type: Application
    Filed: August 26, 2014
    Publication date: October 13, 2016
    Applicant: Celsense, Inc.
    Inventors: Brooke M. Helfer, Anthony G. Balducci, Charles F. O'Hanlon, III
  • Publication number: 20160235872
    Abstract: Compositions and methods for assessing inflammation in a subject. The preset disclosure provides compositions for labeling leukocytes with a 19F-containing perfluoropolyether molecule ex vivo. In some examples, the leukocytes are obtained from the patient, enriched in a whole blood fraction, and then labeled. The labeled cells may be re-introduced into the patient. The leukocytes may accumulate at a site of inflammation, thus permitting non-invasive evaluation of inflammation in patients. The present methods provide a tool for assessing inflammation in a wide variety of autoimmune diseases and may have particular utility in intestinal diseases such as Crohn's disease, ulcerative colitis, inflammatory bowel disease, and cardio myositis.
    Type: Application
    Filed: February 12, 2016
    Publication date: August 18, 2016
    Applicant: Celsense, Inc.
    Inventors: Brooke M. Helfer, Anthony G. Balducci, Charles F. O'Hanlon, III
  • Patent number: 9352057
    Abstract: The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell members, in vivo. In certain embodiments, emulsions can be used as an artificial blood substitute.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: May 31, 2016
    Assignee: Celsense, Inc.
    Inventors: Eric T. Ahrens, Jelena Janjic
  • Publication number: 20130343999
    Abstract: The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell members, in vivo. In certain embodiments, emulsions can be used as an artificial blood substrate.
    Type: Application
    Filed: May 24, 2013
    Publication date: December 26, 2013
    Applicant: Celsense, Inc.
    Inventors: Eric T. Ahrens, Jelena Janjic
  • Publication number: 20110110863
    Abstract: The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell numbers in vivo.
    Type: Application
    Filed: May 1, 2009
    Publication date: May 12, 2011
    Applicant: CELSENSE, INC.
    Inventors: Eric T. Ahrens, Jelena Janjic
  • Publication number: 20070258886
    Abstract: The disclosure relates to methods for labeling cells ex vivo with agents that can be detected by MRI or PET techniques, or other techniques that permit non-invasive imaging of living organisms. The labeled cells can be re-administered to the patient and the movements of the labeled cells can be tracked in vivo by MRI, PET or other techniques. In part, the disclosed methods involve labeling a series of cell samples ex vivo determining the association of label with the cells, such that an appropriate dosage of labeled cells can be determined for each patient.
    Type: Application
    Filed: April 16, 2007
    Publication date: November 8, 2007
    Applicant: Celsense Inc.
    Inventors: Eric Ahrens, Paul Kornblith